p53, MDM2, eIF4E and EGFR expression in nasopharyngeal carcinoma and their correlation with clinicopathological characteristics and prognosis: A retrospective study

Oncology Letters

Volumn 9, Issue 1, 2015, Pages 113-118

  Zhang, Peng ^a   Wu, Song Ke ^b   Wang, Ying ^a   Fan, Zi Xuan ^a   Li, Chu Rong ^a   Feng, Mei ^a   Xu, Peng ^a   Wang, Wei Dong ^a   Lang, Jin Yi ^a  

^a SICHUAN CANCER HOSPITAL   (China)

^b Cangxi People's Hospital   (China)

Author keywords

EGFR; eIF4E; Immunohistochemistry; MDM2; Nasopharyngeal carcinoma; P53

Indexed keywords

CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; INITIATION FACTOR 4E; PROTEIN MDM2; PROTEIN P53;

ADULT; AGED; ARTICLE; BLOOD CLOTTING TEST; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; ECHOGRAPHY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTENSITY MODULATED RADIATION THERAPY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NASAL BIOPSY; NASOPHARYNGOSCOPE; NASOPHARYNX CARCINOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SURVIVAL RATE; THORAX RADIOGRAPHY;

EID: 84911380457     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2014.2631     Document Type: Article

References (44)

1. Ho FC, Tham IW, Earnest A, et al: Patterns of regional lymph node metastasis of nasopharyngeal carcinoma: a meta-analysis of clinical evidence. BMC Cancer 12: 98, 2012.
2. Golubovskaya VM, Conway-Dorsey K, Edmiston SN, et al: FAK overexpression and p53 mutations are highly correlated in human breast cancer. Int J Cancer 125: 1735-1738, 2009.
3. Olivier M, Eeles R, Hollstein M, et al: The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat 19: 607-614, 2002.
4. Kondo I, Iida S, Takagi Y and Sugihara K: MDM2 mRNA expression in the p53 pathway may predict the potential of invasion and liver metastasis in colorectal cancer. Dis Colon Rectum 51: 1395-1402, 2008.
5. Sunavala-Dossabhoy G, Palaniyandi S, Clark C, et al: Analysis of eIF4E and 4EBP1 mRNAs in head and neck cancer. Laryngoscope 121: 2136-2141, 2011.
6. Singh J, Jayaraj R, Baxi S, Mileva M, Curtin J and Thomas M: An Australian retrospective study to evaluate the prognostic role of p53 and eIF4E cancer markers in patients with head and neck squamous cell carcinoma (HNSCC): study protocol. Asian Pac J Cancer Prev 14: 4717-4721, 2013.
7. Yin X, Kim RH, Sun G, Miller JK and Li BD: Overexpression of eukaryotic initiation factor 4E is correlated with increased risk for systemic dissemination in node-positive breast cancer patients. J Am Coll Surg 218: 663-671, 2014.
8. Von Pawel J: Gefitinib (Iressa, ZD1839): a novel targeted approach for the treatment of solid tumors. Bull Cancer 91: E70-E76, 2004.
9. Feng M, Wang W, Fan Z, Fu B, Li J, Zhang S and Lang J: Tumor volume is an independent prognostic indicator of local control in nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy. Radiat Oncol 8: 208, 2013.
10. Greene FL, Page DL, et al (eds.): AJCC Cancer Staging Manual. 6th edition. Springer, New York, NY, pp 47-60, 2002.
11. Lee AW, Lin JC and Ng WT: Current management of nasopharyngeal cancer. Semin Radiat Oncol 22: 233-244, 2012.
12. Berg M and Soreide K: EGFR and downstream genetic alterations in KRAS/BRAF and PI3K/AKT pathways in colorectal cancer: implications for targeted therapy. Discov Med 14: 207-214, 2012.
13. Baselga J: The EGFR as a target for anticancer therapy - focus on cetuximab. Eur J Cancer 37: S16-S22, 2001.
14. Nicholson RI, Gee JM and Harper ME: EGFR and cancer prognosis. Eur J Cancer 37 (Suppl 4): S9-S15, 2001.
15. Meek DW: Tumour suppression by p53: a role for the DNA damage response? Nat Rev Cancer 9: 714-723, 2009.
16. Chang LJ and Eastman A: Decreased translation of p21 (waf1) mRNA causes attenuated p53 signaling in some p53 wild-type tumors. Cell Cycle 11: 1818-1826, 2012.
17. Seong HA and Ha H: Murine protein serine/threonine kinase 38 activates p53 function through Ser15 phosphorylation. J Biol Chem 287: 20797-20810, 2012.
18. Yin Y, Stephen CW, Luciani MG, et al: p53 stability and activity is regulated by mdm2-mediated induction of alternative p53 translation products. Nat Cell Biol 46: 462-467, 2002.
19. Camus S, Ménendez S, Fernandes K, et al: The p53 isoforms are differentially modified by Mdm2. Cell Cycle 11: 1646-1655, 2012.
20. Huang L, Yan Z, Liao X, et al: The p53 inhibitors MDM2/MDMX complex is required for control of p53 activity in vivo. Proc Natl Acad Sci 108: 12001-12006, 2011.
21. Nicholson J and Hupp TR: The molecular dynamics of MDM2. Cell Cycle 9: 1878-1881, 2010.
22. De Benedetti A and Graff JR: EIF-4E expression and its role in malignancies and metastases. Oncogene 23: 3189-3199, 2004.
23. Zimmer SG, DeBenedetti A and Graff JR: Translational control of malignancy: the mRNA cap-binding protein, eIF-4E, as a central regulator of tumor formation, growth, invasion and metastasis. Anticancer Res 20: 1343-1351, 2000.
24. Stark AM, Hugo HH, Witzel P, et al: Age-related expression of p53, Mdm2, EGFR and Msh2 in glioblastoma multiforme. Zentralbl Neurochir 64: 30-36, 2003.
25. Ushio Y, Tada K, Shiraishi S, et al: Correlation of molecular genetic analysis of p53, MDM2, p16, PTEN, and EGFR and survival of patients with anaplastic astrocytoma and glioblastoma. Front Biosci 1: 281-288, 2003.
26. Halatsch ME, Schmidt U, Unterberg A and Vougioukas VI: Uniform MDM2 overexpression in a panel of glioblastoma multiforme cell lines with divergent EGFR and p53 expression status. Anticancer Res 26: 4191-4194, 2006.
27. Pan J, Tang T, Xu L, et al: Prognostic significance of expression of cyclooxygenase-2, vascular endothelial growth factor, and epidermal growth factor receptor in nasopharyngeal carcinoma. Head Neck 35: 1238-1247, 2013.
28. Esteve A, Lehman T, Jiang W, et al: Correlation of p53 mutations with epidermal growth factor receptor overexpression and absence of mdm2 amplification in human esophageal carcinomas. Mol Carcinog 8: 306-311, 1993.
29. Deb SP, Muñoz RM, Brown DR, et al: Wild-type human p53 activates the human epidermal growth factor receptor promoter. Oncogene 9: 1341-1349, 1994.
30. Korkolopoulou P, Christodoulou P, Kouzelis K, et al: MDM2 and p53 expression in gliomas: a multivariate survival analysis including proliferation markers and epidermal growth factor receptor. Br J Cancer 75: 1269-1278, 1997.
31. Harada K, Kurisu K, Tahara H, et al: Telomerase activity in primary and secondary glioblastomas multiforme as a novel molecular tumor marker. J Neurosurg 93: 618-625, 2000.
32. Halatsch ME, Schmidt U, Botefur IC, et al: Overexpression of deletion-mutant epidermal growth factor receptor is associated with altered genotoxic stress-provoked p53 mRNA induction in a human glioblastoma cell line. Anticancer Res 21: 189-195, 2001.
33. Kleihues P and Ohgaki H: Primary and secondary glioblastomas: from concept to clinical diagnosis. Neuro Oncol 1: 44-51, 1999.
34. Stark AM, Hugo HH, Witzel P, et al: Age-related expression of p53, Mdm2, EGFR and Msh2 in glioblastoma multiforme. Zentralbl Neurochir 64: 30-36, 2003.
35. Houillier C, Lejeune J, Benouaich-Amiel A, et al: Prognostic impact of molecular markers in a series of 220 primary glioblastomas. Cancer 106: 2218-2223, 2006.
36. Dehais C, Laigle-Donadey F, Marie Y, et al: Prognostic stratification of patients with anaplastic gliomas according to genetic profile. Cancer 107: 1891-1897, 2006.
37. Ruano Y, Ribalta T, de Lope AR, et al: Worse outcome in primary glioblastoma multiforme with concurrent epidermal growth factor receptor and p53 alteration. Am J Clin Path 131: 257-263, 2009.
38. Ruiz C, Seibt S, Al Kuraya K, et al: Tissue microarrays for comparing molecular features with proliferation activity in breast cancer. Int J Cancer 118: 2190-2194, 2006.
39. Berghmans T, Mascaux C, Haller A, et al: EGFR, TTF-1 and Mdm2 expression in stage III non-small cell lung cancer: a positive association. Lung Cancer 62: 35-44, 2008.
40. Schaefer IM, Sahlmann CO, Overbeck T, et al: Blastomatoid pulmonary carcinosarcoma: report of a case with a review of the literature. BMC Cancer 12: 424, 2012.
41. Vasei M, Modjtahedi H, Ale-Booyeh O, et al: Amplification and expression of EGFR and ERBB2 in Wilms tumor. Cancer Genet Cytogenet 194: 88-95, 2009.
42. Wiseman SM, Masoudi H, Niblock P, et al: Anaplastic thyroid carcinoma: expression profile of targets for therapy offers new insights for disease treatment. Ann Surg Oncol 14: 719-729, 2007.
43. Baffa R, Letko J, McClung C, LeNoir J, Vecchione A and Gomella LG: Molecular genetics of bladder cancer: targets for diagnosis and therapy. J Exp Clin Cancer Res 25: 145-160, 2006.
44. Bianco R, Caputo R, Caputo R, Damiano V, De Placido S, Ficorella C, et al: Combined targeting of epidermal growth factor receptor and MDM2 by gefitinib and antisense MDM2 cooperatively inhibit hormone-independent prostate cancer. Clin Cancer Res 10: 4858-4864, 2004.